Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.